Insider Selling: Twist Bioscience (NASDAQ:TWST) SVP Sells $136,347.80 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 1,007 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $136,347.80. Following the transaction, the senior vice president directly owned 105,625 shares in the company, valued at $14,301,625. This trade represents a 0.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paula Green also recently made the following trade(s):

• On Friday, October 2nd, Paula Green sold 10,088 shares of Twist Bioscience stock. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44.
• On Monday, September 21st, Paula Green sold 294 shares of Twist Bioscience stock. The stock was sold at an average price of $165.49, for a total value of $48,654.06.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $120.79 on Friday. The stock has a market capitalization of $7.57 billion, a P/E ratio of -54.41 and a beta of 2.25. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $219.71. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average price of $151.35 and a two-hundred day moving average price of $91.08.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in the stock. Abacus Wealth Partners LLC increased its position in Twist Bioscience by 4.3% during the third quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company’s stock worth $451,000 after acquiring an additional 96 shares during the period. Root Financial Partners LLC bought a new stake in Twist Bioscience in the 3rd quarter valued at about $33,000. GAMMA Investing LLC boosted its holdings in Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares during the period. Abel Hall LLC boosted its holdings in Twist Bioscience by 3.6% in the 3rd quarter. Abel Hall LLC now owns 5,514 shares of the company’s stock valued at $1,066,000 after purchasing an additional 191 shares during the period. Finally, Allworth Financial LP grew its position in shares of Twist Bioscience by 54.9% during the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock worth $62,000 after purchasing an additional 213 shares in the last quarter.

Wall Street Analyst Weigh In

TWST has been the subject of several analyst reports. Piper Sandler lifted their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group boosted their price target on shares of Twist Bioscience from $120.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Barclays raised their price objective on shares of Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Finally, BWS Financial reaffirmed a “sell” rating and set a $45.00 target price on shares of Twist Bioscience in a report on Friday, September 18th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $153.00.

Key Stories Impacting Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist launched MRD Express, potentially expanding its presence in minimal residual disease testing. Investors may look for further details on the product and business outlook around earnings. Article: Twist Bioscience stock enters earnings week after MRD Express launch
• Neutral Sentiment: CEO Emily Leproust and three other insiders sold a combined 6,677 shares at $135.40. The sales were disclosed as covering tax withholding on equity-award vesting, and each seller retained a substantial stake.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The provided article headline does not specify the report’s allegations, but its release appears to have hurt sentiment. Article: Twist Bioscience falls amid negative report

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.